IL6 and endothelial dysfunction: Most of them, including corticosteroids, heparin, serine protease inhibitors, and biological agents targeting inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) or their receptors, have the ability to act at least in part by counteracting endothelial dysfunction and the imbalanced prothrombotic properties of the endothelium through direct or indirect mechanisms [106,107].